Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224029 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
A Phase 4 study of Detrusor Hyperreflexia, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT00224029 is a Phase 4 study of Detrusor Hyperreflexia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 24 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT00224029, a Phase 4 study of Detrusor Hyperreflexia, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
Conditions Studied
Interventions
- DRUG Oxybutynin transdermal system
Study Locations (6)
North Carolina
- - Chapel Hill
- - Charlotte
Texas
- - Dallas
- - Houston
Georgia
- - Atlanta
New York
- - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224029
The ClinicalTrials.gov registry entry for NCT00224029 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Detrusor Hyperreflexia appearing as the primary indexed condition, and to 1 intervention - of which Oxybutynin transdermal system is the first listed.
NCT00224029 reports 6 study locations spanning 4 distinct geographic areas - top geographies include North Carolina, Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT00224029 about?
NCT00224029 is a clinical study titled "A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition". This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
What is the current status of trial NCT00224029?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2004-12. Estimated completion is 2008-05.
What conditions does trial NCT00224029 study?
This clinical trial studies the following conditions: Detrusor Hyperreflexia.
What interventions are being tested in trial NCT00224029?
The interventions under investigation include: Oxybutynin transdermal system (DRUG).
Who is sponsoring clinical trial NCT00224029?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00224029 being conducted?
This trial has 6 study locations across Georgia, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Detrusor Hyperreflexia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.